Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

0.9652 -0.0251 (-2.53%)

Delayed Quote Updated: 2:51 PM EST, Nov 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

May 02, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Changes to Board of Directors

April 29, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗

March 07, 2024

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Lineage Cell Therapeutics: Q4 Earnings Insights ↗

March 07, 2024

Via Benzinga

A Preview Of Lineage Cell Therapeutics's Earnings ↗

March 06, 2024

Via Benzinga

Lineage Cell Therapeutics: Q3 Earnings Insights ↗

November 09, 2023

Via Benzinga

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

April 30, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 07, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Preview: Lineage Cell Therapeutics ↗

November 08, 2023

Via Benzinga

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

April 01, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024

February 29, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

March 18, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

February 14, 2024

Via Benzinga

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

March 13, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

March 11, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

February 09, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For March 7, 2024 ↗

March 07, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.

Via Benzinga

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

February 13, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

February 06, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 01, 2024

Via Benzinga

RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS

January 16, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying ↗

January 03, 2024

The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 29, 2023

Via Benzinga

3 Penny Stocks to Buy for the Next Bull Run ↗

November 11, 2023

While penny stocks to buy represent a terribly risky venture, it’s possible that maybe one of these ideas could skyrocket.

Via InvestorPlace

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 09, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

December 18, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023

November 01, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting

October 24, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks ↗

October 17, 2023

Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them.

Via InvestorPlace

Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells

October 11, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.